Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-ready asset, and…
DURHAM, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in…
Industry-leading balance sheet with $841 million in cash and short-term investments Increased 2023 operating expense savings target to $20 to…
LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a…
– In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6…
On track to release top-line data of potentially pivotal ANAVEX®2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial in the second half…
Q2 Revenues of $28.8 millionQ2 GAAP operating income $0.8 million, adjusted operating income $3.6 millionStrong H1 operating cash flow drove…
Actions bring sharpened focus on MCM and NARCAN® Nasal Spray products Expected to improve operational efficiencies and deliver annual cost…
Robust growth and efficient expense execution continuesBOSTON and ROLLE, Switzerland, Aug. 08, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq:…
Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer’s Disease Commenced Recruitment for 540-patient Phase 2…